Takeda's Zasocitinib Shows Superior Efficacy Over Deucravacitinib in Phase 3 Trial
核心洞察
Takeda's oral TYK2 (搜索) inhibitor zasocitinib (TAK-279) showed statistical superiority to deucravacitinib across the primary and all key secondary endpoints in the Phase 3 LATITUDE Atlas head-to-head study.
At week 16, 36.5% of zasocitinib-treated patients achieved PASI 100 versus 13.9% on deucravacitinib, with higher complete clearance rates seen from week 8.
Long-term LATITUDE PsO 3001 and 3002 data showed durable skin clearance through week 52 and improvements in itch and quality of life from week 2.
Takeda reported new Phase 3 data for zasocitinib (TAK-279), an investigational oral tyrosine kinase 2 (TYK2 (搜索)) inhibitor, in adults with moderate-to-severe plaque psoriasis (搜索), presented at the EADV Congress 2026. In the head-to-head LATITUDE Atlas (TAK-279 PsO 3004) study, zasocitinib demonstrated statistical superiority over deucravacitinib across the primary and all key secondary efficacy endpoints, with higher rates of complete skin clearance observed as early as week 8.
At week 16, 36.5% of patients on zasocitinib (n=301) achieved PASI 100 versus 13.9% on deucravacitinib (n=303; p<0.001), more than 2.5 times as many patients. PASI 90 was reached by 62.5% versus 34.0%, and sPGA 0 by 43.2% versus 18.5% (both p<0.001). Zasocitinib was generally well tolerated with no new safety signals; the most common adverse events across the Phase 3 LATITUDE psoriasis trials were upper respiratory tract infection, nasopharyngitis and acne.
Long-term data from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance through week 52, with up to 93% of week 24 responders maintaining clearance through week 52 in PsO 3001 (post-hoc) and week 40 in PsO 3002. Patients reported improvements in itch and quality of life as early as week 2, with continued gains through week 24, versus placebo and apremilast. Zasocitinib is under review by the FDA and EMA for moderate-to-severe plaque psoriasis (搜索), and is being evaluated in Phase 3 psoriatic arthritis (搜索) and Phase 2 Crohn's disease (搜索), ulcerative colitis (搜索), vitiligo (搜索) and hidradenitis suppurativa (搜索) studies.
Source: Takeda news release